Ubix Therapeutics develops novel anti-cancer drugs based on Degraducer® platform technology. Degraducer® is a powerful, next-generation inhibitor technology that enables targeting of disease-related targets that were previously undruggable. We are developing novel anti-cancer therapies based on conscientious research and understanding of the human immune system and target proteins. Our goal is to increase life span and improve quality of life for affected patients.

Degraducer® Technology : Small molecular compounds focus on inhibiting the function of disease-related proteins. However, a new concept that rather eliminates the disease-related proteins has emerged. It is a rising strategy that not only pursues previously undruggable disease targets, but also overcomes resistance attributable to pre-existing drugs. Intracellular protein degradation takes place via two pathways led by lysosome and proteasome. Most intracellular proteins are tagged by ubiquitin and are degraded by proteasome in the cytoplasm and the nucleus. This purification process is termed the Ubiquitin-Proteasome System (UPS). Degraducer® is a technology that utilizes the UPS system. It is a bifunctional molecule where “ligand”, which binds to the target protein, and “binder”, which binds to the E3 ubiquitin ligase, are connected by a linker. Degraducer® is a powerful inhibitor technology that enables targeted protein degradation and consequent therapeutic effects by placing a disease-related target protein nearby E3 ligase, which is an enzyme that can initiate the protein degradation system.

Private

Biotech